Osimertinib Improves Disease-Free Survival in Patients with EGFR-Mutated Advanced NSCLC

Phase III data, presented at the 2020 ASCO Virtual Scientific Program, showed that treatment with osimertinib dramatically improved disease-free survival compared to placebo for patients with EGFR-mutated advanced NSCLC.

Source: CancerNetwork - May 28, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news